Microtubule-destabilizing SARS-CoV-2 Drug clears Phase III

Sabizabulin (VERU-111), a novel microtubule inhibitor, significantly reduced mortality in hospitalized patients with moderate to severe COVID-19 at high risk for acute respiratory distress syndrome and death according to an interim analysis from a randomized, global phase 3 clinical trial published this week in The New England Journal of Medicine Evidence.

Compared to placebo, sabizabulin resulted in a 24.9% absolute reduction in deaths beginning within the first week of treatment. Sabizabulin also resulted in a reduction of patient days in the ICU and/or on mechanical ventilation. Veru has applied to the Food and Drug Administration for an emergency authorization of use in severely ill COVID patients.

Read our previous story on Phase II

Share This Post

More News...

If you would like to contribute, send us your comment.

Scroll to Top